EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

David F L Liew, Sarah L Mackie, Alice Tison, Sebastian E Sattui, Max Yates, Russell R C Buchanan, Claire E Owen

Rheumatic Disease Clinics of North America · 2024-05 · 50 (2) · 255-267

DOI: 10.1016/j.rdc.2024.02.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024-05. Verfasst von David F L Liew und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, …. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyalgia RheumaticaImmune Checkpoint InhibitorsHumans

Stichwörter der Autor:innen

Disease modelImmune-related adverse eventMimicsPD-1 agonistPD-1 inhibitorParaneoplasticPeresolimabPolymyalgia rheumatica

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg VIC 3084, Australia; Department of Medicine, University of…
  • Division of Rheumatic and Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Worsley Buil…
  • LBAI UMR1227, Univ Brest, Inserm, Brest, France; Department of Rheumatology, CHU Brest, France Boulevard TANGUY PRIGENT, Brest, Brittany 29609, France.
  • Division of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S723, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
  • Norwich Medical School, University of East Anglia, Norwich, UK; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK.
  • Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.

Zitieren

APA

Liew, D. F. L., Mackie, S. L., Tison, A., Sattui, S. E., Yates, M., Buchanan, R. R. C., & Owen, C. E. (2024). Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America, 50(2), 255-267. https://doi.org/10.1016/j.rdc.2024.02.001

Vancouver

Liew DFL, Mackie SL, Tison A, Sattui SE, Yates M, Buchanan RRC, et al. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America. 2024;50(2):255-267. doi:10.1016/j.rdc.2024.02.001

BibTeX
@article{Liew2024,
  author = {Liew, David F L and Mackie, Sarah L and Tison, Alice and Sattui, Sebastian E and Yates, Max and Buchanan, Russell R C and Owen, Claire E},
  title = {Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica},
  journal = {Rheumatic Disease Clinics of North America},
  year = {2024},
  volume = {50},
  number = {2},
  pages = {255--267},
  doi = {10.1016/j.rdc.2024.02.001}
}
Kostenlos starten →